1.Bioequivalence study of pyrazinamide tablets in Chinese healthy subjects
Li-Bing YE ; Chong YAO ; Ying-Rong CHEN ; Lu-Yuan TONG ; Tao YANG ; Xiao LU ; Min XU ; Qiu-Yue JIN ; Shui-Xin YANG
The Chinese Journal of Clinical Pharmacology 2024;40(15):2236-2240
Objective To evaluate the bioequivalence and safety of two pyrazinamide tablets in healthy Chinese subjects.Methods An open,randomized,single-dose,two-sequence,two-cycle,double-cross trial design was used.All 48 healthy subjects(24 in fasting and 24 in fed trial)were randomized to receive a single oral dose of a 0.5 g pyrazinamide tablet(test or reference)per cycle.The plasma concentration of the drug was determined by liquid chromatography coupled to tandem mass spectrometry method.The pharmacokinetic parameters were calculated by WinNonlin v8.2,and the bioequivalence was evaluated by SAS 9.4.Results In the fasting group,the Cmax of the test and reference preparation of pyrazinamide tablets were(13.28±2.82)and(12.88±4.49)μg·mL-1,the AUC0-t were(139.17±26.58)and(138.63±28.92)h·μg·mL-1,the AUC0-∞ were(148.96±33.65)and(148.71±36.97)h·μg·mL-1 respectively.In the fed group,the Cmax of the test and reference preparation of pyrazinamide tablets were(11.89±1.96)and(11.99±1.92)μg·mL-1,the AUC0-t were(138.22±37.21)and(141.68±25.80)h·μg·mL-1,the AUC0-∞ were(152.20±32.41)and(151.04±28.05)h·μg·mL-,respectively.The 90%confidence intervals of Cmax,AUC0-t and AUC0-∞ geometric mean ratios of the test and reference preparation were all within 80.00%to 125.00%.The incidence of adverse events was 16.70%for both the test and reference preparation in the fasting group and 8.30%for both the test and reference preparation in the fed group,all of which were mild in severity.Conclusion The test and reference preparation of pyrazinamide tablets were bioequivalent,safe and well tolerated in healthy Chinese subjects under fasting and fed conditions.
2.Diagnostic and intervention value of implantable cardiac monitor in patients over 60 years of age with unexplained syncope
Rui WANG ; Yanfei ZHANG ; Hongchao ZHANG ; Jia WANG ; Shuhui SHEN ; Jiabin TONG ; Junpeng LIU ; You LYU ; Jia CHONG ; Zhilei WANG ; Xin JIN ; Lin SUN ; Xu GAO ; Yan DAI ; Jing LIANG ; Haitao LI ; Tong ZOU ; Jiefu YANG
Chinese Journal of Cardiology 2024;52(7):784-790
Objective:To investigate the value of implantable cardiac monitor (ICM) in the diagnosis and treatment of patients over 60 years old with unexplained syncope.Methods:This was a multi-center, prospective cohort study. Between June 2018 and April 2021, patients over the age of 60 with unexplained syncope at Beijing Hospital, Fuwai Hospital, Beijing Anzhen Hospital and Puren Hospital were enrolled. Patients were divided into 2 groups based on their decision to receive ICM implantation (implantation group and conventional follow-up group). The endpoint was the recurrence of syncope and cardiogenic syncope as determined by positive cardiac arrhythmia events recorded at the ICM or diagnosed during routine follow-up. Kaplan‐Meier survival analysis was used to compare the differences of cumulative diagnostic rate between the 2 groups. A multivariate Cox regression analysis was performed to determine independent predictors of diagnosis of cardiogenic syncope in patients with unexplained syncope.Results:A total of 198 patients with unexplained syncope, aged (72.9±8.25) years, were followed for 558.0 (296.0,877.0) d, including 98 males (49.5%). There were 100 (50.5%) patients in the implantation group and 98 (49.5%) in the conventional follow-up group. Compared with conventional follow-up group, patients in the implantation group were older, more likely to have comorbidities, had a higher proportion of first degree atrioventricular block indicated by baseline electrocardiogram, and had a lower body mass index (all P<0.05). During the follow-up period, positive cardiac arrhythmia events were recorded in 58 (58.0%) patients in the ICM group. The diagnosis rate (42.0% (42/100) vs. 4.1% (4/98), P<0.001) and the intervention rate (37.0% (37/100) vs. 2.0% (2/98), P<0.001) of cardiogenic syncope in the implantation group were higher than those in the conventional follow-up group (all P<0.001). Kaplan-Meier survival analysis showed that the cumulative diagnostic rate of cardiogenic syncope was significantly higher in the implantation group than in the traditional follow-up group ( HR=11.66, 95% CI 6.49-20.98, log-rank P<0.001). Multivariate analysis indicated that ICM implantation, previous atrial fibrillation, diabetes mellitus or first degree atrioventricular block in baseline electrocardiogram were independent predictors for cardiogenic syncope (all P<0.05). Conclusions:ICM implantation improves the diagnosis and intervention rates in patients with unexplained syncope, and increases diagnostic efficiency in patients with unexplained syncope.
3.Multimodal prerehabilitation for elderly patients with sarcopenia in colorectal surgery
Jingting WU ; Hannah CHI ; Shawn KOK ; Jason M.W. CHUA ; Xi-Xiao HUANG ; Shipin ZHANG ; Shimin MAH ; Li-Xin FOO ; Hui-Yee PEH ; Hui-Bing LEE ; Phoebe TAY ; Cherie TONG ; Jasmine LADLAD ; Cheryl H.M. TAN ; Nathanelle KHOO ; Darius AW ; Cheryl X.Z. CHONG ; Leonard M.L. HO ; Sharmini S. SIVARAJAH ; Jialin NG ; Winson J.H. TAN ; Fung-Joon FOO ; Bin-Tean TEH ; Frederick H. KOH
Annals of Coloproctology 2024;40(1):3-12
Sarcopenia, which is characterized by progressive and generalized loss of skeletal muscle mass and strength, has been well described to be associated with numerous poor postoperative outcomes, such as increased perioperative mortality, postoperative sepsis, prolonged length of stay, increased cost of care, decreased functional outcome, and poorer oncological outcomes in cancer surgery. Multimodal prehabilitation, as a concept that involves boosting and optimizing the preoperative condition of a patient prior to the upcoming stressors of a surgical procedure, has the purported benefits of reversing the effects of sarcopenia, shortening hospitalization, improving the rate of return to bowel activity, reducing the costs of hospitalization, and improving quality of life. This review aims to present the current literature surrounding the concept of sarcopenia, its implications pertaining to colorectal cancer and surgery, a summary of studied multimodal prehabilitation interventions, and potential future advances in the management of sarcopenia.
4.Regional analysis of high risk factors of hypertensive disorders in pregnancy with organ or system impairment.
Xin LYU ; Wei Yuan ZHANG ; Jing Xiao ZHANG ; Yu Qian WEI ; Xiao Li GUO ; Shi Hong CUI ; Jian Ying YAN ; Xiao Yan ZHANG ; Chong QIAO ; Rong ZHOU ; Wei Rong GU ; Xian Xia CHEN ; Zi YANG ; Xiao Tian LI ; Jian Hua LIN
Chinese Journal of Obstetrics and Gynecology 2023;58(6):416-422
Objective: To explore the influencing factors of pregnancy-induced hypertensive disorders in pregnancy (HDP) with organ or system impairment in pregnant women, and to analyze and compare the differences of HDP subtypes in different regions of China. Methods: A total of 27 680 pregnant women with HDP with complete data from 161 hospitals in 24 provinces, autonomous regions and municipalities were retrospectively collected from January 1, 2018 to December 31, 2018. According to their clinical manifestations, they were divided into hypertension group [a total of 10 308 cases, including 8 250 cases of gestational hypertension (GH), 2 058 cases of chronic hypertension during pregnancy] and hypertension with organ or system impairment group [17 372 cases, including 14 590 cases of pre-eclampsia (PE), 137 cases of eclampsia, 2 645 cases of chronic hypertension with PE]. The subtype distribution of HDP in East China (6 136 cases), North China (4 821 cases), Central China (3 502 cases), South China (8 371 cases), Northeast China (1 456 cases), Southwest China (2 158 cases) and Northwest China (1 236 cases) were analyzed. By comparing the differences of HDP subtypes and related risk factors in different regions, regional analysis of the risk factors of HDP pregnant women with organ or system impairment was conducted. Results: (1) The proportions of HDP pregnant women with organ or system impairment in Northeast China (79.05%, 1 151/1 456), Central China (68.42%, 2 396/3 502) and Northwest China (69.34%, 857/1 236) were higher than the national average (62.76%, 17 372/27 680); the proportions in North China (59.18%, 2 853/4 821), East China (60.85%, 3 734/6 136) and South China (59.56%, 4 986/8 371) were lower than the national average, and the differences were statistically significant (all P<0.05). (2) Univariate analysis showed that the proportions of primiparas, non-Han, non-urban household registration, irregular prenatal examination and PE history in the hypertension with organ or system impairment group were higher than those in the hypertension group, and the differences were statistically significant (all P<0.05). Multivariate logistic regression analysis showed that primiparas, non-Han, non-urban household registration, irregular prenatal examination and PE history were independent risk factors for HDP pregnant women with organ or system impairment (all P<0.05). (3) Primipara: the rates of primipara in Northeast China, North China and Southwest China were higher than the national average level, while those in South China, Central China and Northwest China were lower than the national average level. Non-Han nationality: the rates of non-Han nationality in Northeast China, North China and Northwest China were higher than the national average, while those in East China, South China and Central China were lower than the national average. Non-urban household registration: the rates of non-urban household registration in Northeast China, North China, and Southwest China were lower than the national average, while those in East China, Central China were higher than the national average. Irregular prenatal examination: the rates of irregular prenatal examination in North China, South China and Southwest regions were lower than the national average level, while those in Northeast China, Central China and Northwest China were higher than the national average level. History of PE: the incidence rates of PE in Northeast China, North China, South China and Southwest China were lower than the national average level, while those in Central China and Northwest China were higher than the national average level. Conclusions: Primiparas, non-Han, non-urban household registration, irregular prenatal examination, and PE history are risk factors for HDP pregnant women with organ or system impairment. Patients in Northeast, Central and Northwest China have more risk factors, and are more likely to be accompanied by organ or system function damage. It is important to strengthen the management of pregnant women and reduce the occurrence of HDP.
Humans
;
Pregnancy
;
Female
;
Hypertension, Pregnancy-Induced/diagnosis*
;
Retrospective Studies
;
Pre-Eclampsia/epidemiology*
;
Risk Factors
;
Incidence
5.A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models.
Qi WU ; Lan CHEN ; Xiaojuan HUANG ; Jiayi LIN ; Jiamin GAO ; Guizhu YANG ; Yaping WU ; Chong WANG ; Xindan KANG ; Yanli YAO ; Yujue WANG ; Mengzhu XUE ; Xin LUAN ; Xin CHEN ; Zhiyuan ZHANG ; Shuyang SUN
International Journal of Oral Science 2023;15(1):9-9
Cancer cell membrane (CCM) derived nanotechnology functionalizes nanoparticles (NPs) to recognize homologous cells, exhibiting translational potential in accurate tumor therapy. However, these nanoplatforms are majorly generated from fixed cell lines and are typically evaluated in cell line-derived subcutaneous-xenografts (CDX), ignoring the tumor heterogeneity and differentiation from inter- and intra- individuals and microenvironments between heterotopic- and orthotopic-tumors, limiting the therapeutic efficiency of such nanoplatforms. Herein, various biomimetic nanoplatforms (CCM-modified gold@Carbon, i.e., Au@C-CCM) were fabricated by coating CCMs of head and neck squamous cell carcinoma (HNSCC) cell lines and patient-derived cells on the surface of Au@C NP. The generated Au@C-CCMs were evaluated on corresponding CDX, tongue orthotopic xenograft (TOX), immune-competent primary and distant tumor models, and patient-derived xenograft (PDX) models. The Au@C-CCM generates a photothermal conversion efficiency up to 44.2% for primary HNSCC therapy and induced immunotherapy to inhibit metastasis via photothermal therapy-induced immunogenic cell death. The homologous CCM endowed the nanoplatforms with optimal targeting properties for the highest therapeutic efficiency, far above those with mismatched CCMs, resulting in distinct tumor ablation and tumor growth inhibition in all four models. This work reinforces the feasibility of biomimetic NPs combining modular designed CMs and functional cores for customized treatment of HNSCC, can be further extended to other malignant tumors therapy.
Animals
;
Humans
;
Squamous Cell Carcinoma of Head and Neck/therapy*
;
Heterografts
;
Photothermal Therapy
;
Biomimetics
;
Disease Models, Animal
;
Head and Neck Neoplasms/therapy*
;
Cell Line, Tumor
;
Tumor Microenvironment
6.Correction To: A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models.
Qi WU ; Lan CHEN ; Xiaojuan HUANG ; Jiayi LIN ; Jiamin GAO ; Guizhu YANG ; Yaping WU ; Chong WANG ; Xindan KANG ; Yanli YAO ; Yujue WANG ; Mengzhu XUE ; Xin LUAN ; Xin CHEN ; Zhiyuan ZHANG ; Shuyang SUN
International Journal of Oral Science 2023;15(1):12-12
8.Publishing clinical prActice GuidelinEs (PAGE): Recommendations from editors and reviewers.
Nan YANG ; Wei ZHAO ; Wen-An QI ; Chen YAO ; Chong-Ya DONG ; Zhen-Guo ZHAI ; Tong CHEN ; En-Mei LIU ; Guo-Bao LI ; You-Lin LONG ; Xin-Yi WANG ; Zi-Jun WANG ; Ruo-Bing LEI ; Qi ZHOU ; Yao-Long CHEN ; Liang DU
Chinese Journal of Traumatology 2022;25(6):312-316
Transparency Ecosystem for Research and Journals in Medicine (TERM) working group summarized the essential recommendations that should be considered to review and publish a high-quality guideline. These recommendations from editors and reviewers included 10 components of essential requirements: systematic review of existing relevant guidelines, guideline registration, guideline protocol, stakeholders, conflicts of interest, clinical questions, systematic reviews, recommendation consensus, guideline reporting and external review. TERM working group abbreviates them as PAGE (essential requirements for Publishing clinical prActice GuidelinEs), and recommends guideline authors, editors, and peer reviewers to use them for high-quality guidelines.
Humans
;
Practice Guidelines as Topic
9.New anti-pulmonary fibrosis prenylflavonoid glycosides from Epimedium koreanum.
Yu-Dan ZHAO ; Xin ZHANG ; Wan-Yue YANG ; Rui-Qi ZHANG ; Lin-Tong MU ; Ling HAN ; Chong-Ning LV ; Jin-Cai LU
Chinese Journal of Natural Medicines (English Ed.) 2022;20(3):221-228
Four new prenylflavonoid glycosides, namely koreanoside H-K (1-4), together with eleven known ones (5-15) were isolated from the leaves of Epimedium koreanum Nakai. Their structures were elucidated by 1D NMR, 2D NMR, HR-ESI-MS, IR and UV. The identification of the sugar moieties was carried out by means of acid hydrolysis and HPLC analysis of their derivatives. It is worth noting that compound 3 and compound 4 were elucidated to contain fucose and quinovose moieties, which were two extremely rare sugar units from the genus Epimedium. The anti-pulmonary fibrosis activity of the new compounds was evaluated using A549 cell line. Compounds 1, 2 and 4 showed significant anti-pulmonary fibrosis activities.
Chromatography, High Pressure Liquid
;
Epimedium/chemistry*
;
Glycosides/pharmacology*
;
Plant Extracts/pharmacology*
;
Plant Leaves/chemistry*
10.Rescue of male infertility through correcting a genetic mutation causing meiotic arrest in spermatogonial stem cells.
Ying-Hua WANG ; Meng YAN ; Xi ZHANG ; Xin-Yu LIU ; Yi-Fu DING ; Chong-Ping LAI ; Ming-Han TONG ; Jin-Song LI
Asian Journal of Andrology 2021;23(6):590-599
Azoospermia patients who carry a monogenetic mutation that causes meiotic arrest may have their biological child through genetic correction in spermatogonial stem cells (SSCs). However, such therapy for infertility has not been experimentally investigated yet. In this study, a mouse model with an X-linked testis-expressed 11 (TEX11) mutation (Tex11
Adult Germline Stem Cells/metabolism*
;
Animals
;
Azoospermia/genetics*
;
Infertility, Male/therapy*
;
Male
;
Mice
;
Mutation/genetics*
;
Spermatogenesis/genetics*

Result Analysis
Print
Save
E-mail